Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
Tags :Oliver Gnehm
GOLDBEK Holding, a fast growing and innovative German greeting card publishing company, has acquired 100% of ABC Kunst- und Glückwunschkartenverlag (its legal name is A. Boss & Co), a privately owned Swiss market leader in
Samsung Ventures has made a strategic investment in Araris Biotech. The investment corporation, that was established to promote the development of new technologies, has invested in the company in an independent deal ahead of its
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. Through this
BGPartner has advised Araris Biotech in a CHF 24 million financing round, involving the two co-lead investors 4BIO Capital and Pureos Bioventures. Araris Biotech, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the
Lalique Group has signed an agreement to acquire the long-established silk label Fabric Frontline. Founded in Zurich over 40 years ago, the company gained international recognition with its high-quality silk collections that combine quality awareness, individual
BGPartner has advised in acquisition of tradition Hotel Florhof in Zurich. Silvio Denz, majority shareholder and chairman of Lalique Group, together with entrepreneur Peter Spuhler, have acquired the Hotel Florhof in Zurich, a Zurich hotel
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination
The Swiss e-commerce agency and software house specializing in the design, development and operation of e-commerce solutions for SMEs, MySign has becomes part of the German Allgeier Group. The IT and software services company Allgeier
